MARVIN PEYTON: Open Payments
NPI 1578644803 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$17,310 in 62 payments from 12 companies in 2025. Trend: 2023 $9,048 · 2024 $25,435 · 2025 $17,310
Honoraria: $11,000Travel & lodging: $4,363Food & beverage: $1,947
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 18 | $13,056 |
| Neurocrine BioSciences, Inc. | 14 | $2,414 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $1,461 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $48 |
| Janssen Pharmaceuticals, Inc | 3 | $48 |
| ABBVIE INC. | 3 | $46 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
Products named: Auvelity, TRINTELLIX, REXULTI, CAPLYTA, UZEDY, VRAYLAR, COBENFY, INVEGA SUSTENNA.
Industry payments across OK — which companies pay providers there.
